. 2014 Aug 6;9(8):e104298. doi: 10.1371/journal.pone.0104298

Table 2. Functional characteristics of intracellular processes in CD4+ cells following PHA activation in RA patients before and during therapy.

		Cytoplasmic Ca²⁺			Reactive oxygen species generation			Nitric oxide production	Mitochondrial Ca²⁺
		AUC (U)	Max (rpv)	t_max (s)	AUC (U)	Max (rpv)	t_max (s)	AUC (U)	AUC (U)
Control (n = 9)		89.06 [62.60–131.5]	1.211 [1.149–1.326]	444.8[192.3–594.4]	75.43[68.01–88.80]	1.239[1.217–1.263]	594.5[594.3–595.3]	5.501[−6.919–35.98]	64.18[42.85–97.89]
Naïve RA (n = 12)	Baseline (without therapy)	90.54 [73.45–206.5]	1.221 [1.166–1.581]	458.9[172.6–594.5]	74.36[50.26–90.26]	1.245[1.178–1.308]	594.5[594.0–595.2]	34.11[−0.103–76.15]	63.03[33.70–97.45]
	Week 4, after medium-dose GCS therapy	44.55^A.B [21.11–74.37]	1.127^A [1.068–1.201]	234.2[209.0–594.1]	48.47^A.B[36.15–79.09]	1.172[1.145–1.237]	594.7[594.3–595.4]	−9.670[−11.43–10.73]	40.11[25.71–58.89]
	Week 8, after low-dose GCS and MTX therapy	60.67 [12.22–111.6]	1.232 [1.046–1.295]	306.5[289.5–594.1]	49.75^A[45.87–54.55]	1.170^A[1.165–1.179]	594.6[594.5–594.8]	3.180[−12.39–11.74]	55.83[19.47–72.22]
Active RA with IFX therapy (n = 7)	Baseline (on LF and MTX therapy)	145.1^A [126.8–207.4]	1.374^A [1.315–1.510]	594.1[342.8–594.6]	65.04[53.47–86.19]	1.223[1.170–1.258]	594.6[594.4–595.2]	24.62[−7.701–95.59]	51.86[44.98–81.62]
	Week 4 of IFX and MTX therapy	96.97 [4.403–162.7]	1.240 [1.032–1.352]	594.5[276.2–594.6]	39.92^A.B[33.42–67.93]	1.146^A[1.141–1.230]	594.4[593.7–595.2]	19.82[−14.59–30.06]	83.87[51.44–166.5]
	Week 8 of IFX and MTX therapy	115.9 [59.33–141.1]	1.328 [1.242–1.347]	593.9[288.0–594.9]	56.16^A[45.14–71.85]	1.186^A[1.167–1.220]	593.6[593.1–595.5]	−2.549[−16.00–25.92]	67.37[42.57–118.9]
Active RA with ETA therapy (n = 7)	Baseline (on LF and MTX therapy)	141.2^A [109.1–235.6]	1.319^A [1.271–1.535]	372.0[216.7–593.5]	94.55^A[81.39–111.0]	1.293[1.242–1.372]	594.9[594.2–595.6]	−0.087[−12.70–22.17]	70.62[59.08–128.8]
	Week 4 of ETA and MTX therapy	125.7 [64.09–159.1]	1.304 [1.147–1.396]	383.8[246.1–594.1]	73.49^B[59.69–81.87]	1.235^B[1.188–1.275]	594.8[594.1–595.3]	21.72[−4.121–87.42]	50.93[34.75–82.80]
	Week 8 of ETA and MTX therapy	92.11 [49.82–222.8]	1.231 [1.182–1.491]	312.5[174.3–593.9]	72.37[49.84–105.9]	1.226[1.163–1.300]	593.9[593.7–594.8]	8.466[−8.267–62.04]	77.45[26.15–94.89]
Active RA with ADA therapy (n = 8)	Baseline (on LF and MTX therapy)	144.4^A [128.0–199.8]	1.399^A [1.320–1.484]	557.9[217.8–594.4]	81.89[69.52–106.8]	1.258[1.220–1.343]	594.5[594.0–594.9]	15.86[1.704–116.9]	77.94[66.09–90.10]
	Week 4 of ADA and MTX therapy	93.91 [77.45–157.3]	1.227 [1.188–1.347]	497.4[256.4–594.6]	63.21^B[34.48–77.15]	1.212[1.155–1.240]	594.7[594.2–595.5]	25.87[−6.588–99.43]	66.84[41.83–92.19]
	Week 8 of ADA and MTX therapy	107.6 [50.18–158.5]	1.262 [1.146–1.364]	432.4[226.6–594.5]	73.95[61.69–78.82]	1.230[1.211–1.241]	594.2[593.6–594.9]	60.43[26.93–133.0]	71.77[62.20–95.48]

Data are expressed as median [interquartile range].

versus control P<0.05;

versus baseline P<0.05.

AUC = area under the curve; Max = maximum value; t_max = time to reach maximum value; rpv = relative parameter value.

GCS = glucocorticosteroid; MTX = methotrexate; LF = leflunomide; IFX = infliximab; ETA = etanercept; ADA = adalimumab; RA = rheumatoid arthritis.